Solid Cancers Clinical Trials

42 clinical trials for Solid Cancers across international registries, including 10 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Clonal Hematopoiesis Chemotherapy and Radiation Effects Study — RECRUITING
• The Effect of Using Weighted Blanket on Anxiety, Stress, Depression and Comfort Level Among Patients With Cancer Undergoing Intravenous Anticancer Therapy and Its Feasibility of Use by Nurses Compared to Routine Care — RECRUITING · NA
• Monitoring of Immunological Mechanisms and Biomarkers Underlying Efficacy and Toxicity of Cancer Immunotherapy — RECRUITING · NA
• xDRIVE for Florida-based Cancer Patients — RECRUITING · NA
• Spatially Fractionated Radiotherapy Combined With Immunotherapy for Advanced Solid Tumors — RECRUITING · PHASE2
• An Antibody-armored Dendritic Cell in Patients With Solid Tumors — RECRUITING · PHASE1
• An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors — RECRUITING · PHASE1
• Phase II Trial of Tunlametinib in Patients With NRAS Mutant Non-melanoma Refractory Solid Tumors — RECRUITING · PHASE2
• A Phase I Study of LXP1788 Injection with Advanced Solid Tumors. — RECRUITING · PHASE1
• 68Ga-PSMA-617 PET/CT for PSMA-expressing Tumor: a Pragmatic Study — RECRUITING
• A Clinical Study of CEA-targeted CAR-T in the Treatment of CEA-positive Advanced Malignant Solid Tumors — COMPLETED · PHASE1
• JY016 Injection in Patients With Advanced Solid Tumors Expressing EGFR — NOT_YET_RECRUITING · PHASE1
• Predicting Reactions and Effects of Drugs Immunotherapy and Complications Through Oncosafety (PREDICTO Clinical Study) — NOT_YET_RECRUITING · NA
• Monitoring of Immunological Mechanisms and Biomarkers Underlying Efficacy of Immunotherapy in Patients With Early Stage Cancer — NOT_YET_RECRUITING · NA
• Serum IGF-1 and IGF-1Ec in Malignancy Assessment — ACTIVE_NOT_RECRUITING
• A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid Tumors — TERMINATED · PHASE1
• A Study to Evaluate the Safety and Tolerability of EP0089 — NOT_YET_RECRUITING · PHASE1
• Real-life Performance Evaluation of the LiFlow X-ray Platform — NOT_YET_RECRUITING
• Application of the sG8 Scale in Real-World Geriatric Oncology Patients — NOT_YET_RECRUITING
• A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway — NOT_YET_RECRUITING · PHASE1
• A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer — TERMINATED · PHASE1
• A Study of the Safety and Pharmacokinetics of MEGF0444A Administered to Patients With Advanced Solid Tumors — COMPLETED · PHASE1
• A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors — COMPLETED · PHASE1
• A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors — COMPLETED · PHASE1
• Phase I Assay-guided Trial of Anti-inflammatory Phytochemicals in Patients With Advanced Cancer — COMPLETED · PHASE1
• A Study of Hedgehog Pathway Inhibitor GDC-0449 in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists — COMPLETED · PHASE1
• A Study of the Safety and Pharmacokinetics of GDC-0152, Administered Intravenously to Patients With Locally Advanced or Metastatic Malignancies — TERMINATED · PHASE1
• A Study of the Safety and Pharmacology of MetMAb (PRO143966), a Monovalent Antagonist Antibody to the Receptor C-Met, Administered Intravenously in Patients With Locally Advanced or Metastatic Solid Tumors — COMPLETED · PHASE1
• A Study of MNRP1685A in Combination With Bevacizumab With or Without Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors — COMPLETED · PHASE1
• A Study of GDC-0941 in Participants With Locally Advanced or Metastatic Solid Tumors for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or Intolerable — COMPLETED · PHASE1
• A Study of the Safety and Pharmacology of MEGF0444A in Combination With Bevacizumab With or Without Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors — COMPLETED · PHASE1
• A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0623 in Patients With Locally Advanced or Metastatic Solid Tumors — COMPLETED · PHASE1
• A Study Evaluating the Safety, Tolerability and Pharmacokinetics of GDC-0917 Administered to Patients With Refractory Solid Tumors or Lymphoma — COMPLETED · PHASE1
• A Study of the Safety and Pharmacokinetics of MINT1526A, Administered Intravenously As a Single Agent and in Combination With Bevacizumab to Patients With Advanced Solid Tumors — COMPLETED · PHASE1
• A Study of the Safety and Pharmacology of GDC-0980 in Combination With Either Paclitaxel and Carboplatin (With or Without Bevacizumab) or Pemetrexed and Cisplatin in Patients With Solid Tumors — COMPLETED · PHASE1
• GDC-0980 in Combination With a Fluoropyrimidine, Oxaliplatin, and Bevacizumab in Patients With Advanced Solid Tumors — COMPLETED · PHASE1
• A Study Evaluating the Safety and Tolerability of GDC-0068 in Patients With Refractory Solid Tumors — COMPLETED · PHASE1
• A Study to Evaluate Corrected QT Interval and Drug-Drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With HER2-Positive Metastatic or Locally Advanced Inoperable Cancer — COMPLETED · PHASE1
• A Study of Pharmacokinetic Drug Interaction Study of the Hedgehog Pathway Inhibitor GDC-0449 in Combination With Rosiglitazone or Combined Oral Contraceptive in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists — COMPLETED · PHASE1
• A Study to Evaluate Subjects Treated With rhuMab 2C4 (Pertuzumab) in a Previous Genentech Phase II Cancer Study — COMPLETED · PHASE2
• A Dose Escalation Study of SF1126, a PI3 Kinase (PI3K) Inhibitor, Given By Intravenous (IV) Infusion in Patients With Solid Tumors — COMPLETED · PHASE1
• A Study of MNRP1685A in Patients With Locally Advanced or Metastatic Solid Tumors — COMPLETED · PHASE1

Refine this search